HER2-positive Advanced Breast Cancer
11
5
5
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
36%
4 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (11)
HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases
T-DM1 Combined With CDK4/6 Inhibitor Ribociclib
DP303c in Patients With HER2-positive Advanced Breast Cancer
Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC
Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer
RWS of Inetetamab HER2 Positive Advanced Breast Cancer
The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer
Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody (GB221) for Injection